Johnson & Johnson OMNY-AF Pilot Hits 100% Success; Price Targets Raised to $255 and $227
Johnson & Johnson’s 12-month OMNY-AF pilot across 30 paroxysmal atrial fibrillation patients achieved 100% acute procedural success with zero procedure-related adverse events and no MRI-detected cerebral lesions across eight centers. RBC Capital raised its price target to $255 and Bank of America to $227, reflecting higher MedTech and pharma multiples.
1. OMNY-AF Pilot Achieves Complete Success
Johnson & Johnson’s pilot-phase OMNY-AF study enrolled 30 symptomatic paroxysmal atrial fibrillation patients across eight centers. Investigators reported 100% acute procedural success, no procedure-related adverse events and no MRI-detected cerebral lesions at 12 months, underscoring strong safety and efficacy for the investigational OMNYPULSE platform.
2. Zero Fluoroscopy and High Effectiveness Rates
The trial demonstrated that 56.7% of procedures were performed without fluoroscopy and 90% of patients met primary effectiveness endpoints at one year. These findings highlight potential reductions in radiation exposure while maintaining durable arrhythmia control in AFib treatment.
3. Analysts Increase Price Targets
Following the study results, RBC Capital raised its price target on the shares to $255 from $240 and Bank of America lifted its target to $227 from $221. Both firms cited expectations of higher MedTech and pharmaceutical multiples driven by robust trial outcomes and the company’s defensive growth profile.